Business Description
Nuvation Bio Inc
NAICS : 541713
SIC : 2834
ISIN : US67080N1019
Share Class Description:
FRA:1E30: Ordinary Shares - Class ATotal Employee Number:
305Description
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.62 | |||||
Equity-to-Asset | 0.34 | |||||
Debt-to-Equity | 0.99 | |||||
Debt-to-EBITDA | -2.08 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 1.63 | |||||
Beneish M-Score | 5.6 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -0.1 | |||||
3-Year EPS without NRI Growth Rate | -4.7 | |||||
3-Year FCF Growth Rate | -6.1 | |||||
3-Year Book Growth Rate | -33.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 86.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.37 | |||||
Quick Ratio | 8.14 | |||||
Cash Ratio | 7.62 | |||||
Days Inventory | 194.1 | |||||
Days Sales Outstanding | 33.36 | |||||
Days Payable | 297.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.6 | |||||
Shareholder Yield % | -3.28 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 88.18 | |||||
Operating Margin % | -81 | |||||
Net Margin % | -88.19 | |||||
EBITDA Margin % | -71.22 | |||||
FCF Margin % | -75.48 | |||||
OCF Margin % | -70.59 | |||||
ROE % | -47.48 | |||||
ROA % | -23.42 | |||||
ROIC % | -275.78 | |||||
3-Year ROIIC % | -153.36 | |||||
ROC (Joel Greenblatt) % | -2710.83 | |||||
ROCE % | -21.87 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 15.41 | |||||
PB Ratio | 10 | |||||
Price-to-Tangible-Book | 10.34 | |||||
EV-to-EBIT | -17.38 | |||||
EV-to-EBITDA | -17.69 | |||||
EV-to-Revenue | 12.6 | |||||
EV-to-Forward-Revenue | 10.69 | |||||
EV-to-FCF | -16.6 | |||||
| Price-to-Net-Current-Asset-Value | 10.85 | |||||
| Price-to-Net-Cash | 14.71 | |||||
Earnings Yield (Greenblatt) % | -5.75 | |||||
FCF Yield % | -5.06 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nuvation Bio Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 146.427 | ||
| EPS (TTM) (€) | -0.377 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 64.69 | ||
| 14-Day ATR (€) | 0.483594 | ||
| 20-Day SMA (€) | 5.60375 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 4.5 - 6.62 | ||
| Shares Outstanding (Mil) | 351.12 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nuvation Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nuvation Bio Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-03 16:30 | In 76 days | ||
| Third quarter earnings results for 2026 | 2026-11-03 | In 75 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 08:00 | 5.53 (+4.34%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 5.53 (+4.34%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 09:55 | -- | ||
| TD Cowen\'s 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA | 2026-05-26 12:00 | -- | ||
| General meeting for 2026 | 2026-05-21 11:00 | -- | ||
| Guidance call for 2026 | 2026-05-20 09:00 | -- | ||
| H.C. Wainwright 4th Annual BioConnect Investor Conference | 2026-05-19 13:30 | -- | ||
| Guidance call for 2026 | 2026-05-13 08:00 | -- |
Show
Entries
Nuvation Bio Inc Frequently Asked Questions
What is Nuvation Bio Inc(FRA:1E30)'s stock price today?
The current price of FRA:1E30 is €6.62. The 52 week high of FRA:1E30 is €6.62 and 52 week low is €4.50.
When is next earnings date of Nuvation Bio Inc(FRA:1E30)?
The next earnings date of Nuvation Bio Inc(FRA:1E30) is 2026-11-03 Est..
Does Nuvation Bio Inc(FRA:1E30) pay dividends? If so, how much?
Nuvation Bio Inc(FRA:1E30) does not pay dividend.
Press Release
Articles on Nuvation Bio Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers